CA3132371A1 - Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction - Google Patents
Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction Download PDFInfo
- Publication number
- CA3132371A1 CA3132371A1 CA3132371A CA3132371A CA3132371A1 CA 3132371 A1 CA3132371 A1 CA 3132371A1 CA 3132371 A CA3132371 A CA 3132371A CA 3132371 A CA3132371 A CA 3132371A CA 3132371 A1 CA3132371 A1 CA 3132371A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- jak1
- subject
- pathway inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814085P | 2019-03-05 | 2019-03-05 | |
| US62/814,085 | 2019-03-05 | ||
| PCT/US2020/021088 WO2020181034A1 (en) | 2019-03-05 | 2020-03-05 | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3132371A1 true CA3132371A1 (en) | 2020-09-10 |
Family
ID=69941525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3132371A Pending CA3132371A1 (en) | 2019-03-05 | 2020-03-05 | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11406640B2 (https=) |
| EP (2) | EP3934651A1 (https=) |
| JP (2) | JP2022524997A (https=) |
| KR (1) | KR20210137087A (https=) |
| CN (1) | CN114007621A (https=) |
| AU (1) | AU2020232757B2 (https=) |
| CA (1) | CA3132371A1 (https=) |
| EA (1) | EA202192426A1 (https=) |
| IL (1) | IL285999B2 (https=) |
| MA (1) | MA55201A (https=) |
| MX (2) | MX2021010545A (https=) |
| PH (1) | PH12021552130A1 (https=) |
| SG (1) | SG11202109563WA (https=) |
| UA (1) | UA130579C2 (https=) |
| WO (1) | WO2020181034A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3837258T (pt) | 2018-09-04 | 2024-06-20 | Theravance Biopharma R&D Ip Llc | Amidas de dimetil amino azetidina como inibidores de jak |
| WO2020051139A1 (en) | 2018-09-04 | 2020-03-12 | Theravance Biopharma R&D Ip, Llc | 5 to 7 membered heterocyclic amides as jak inhibitors |
| MX2021004582A (es) | 2018-10-29 | 2021-06-15 | Theravance Biopharma R&D Ip Llc | Compuesto 2-azabiciclo hexano inhibidor de jak. |
| CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| MA55201A (fr) * | 2019-03-05 | 2022-01-12 | Incyte Corp | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| EP4274578A1 (en) * | 2021-01-11 | 2023-11-15 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
| TW202317550A (zh) | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| KR102952944B1 (ko) | 2021-10-15 | 2026-04-14 | 주식회사 엘지에너지솔루션 | 용접봉 체결 방법 및 이에 의해 용접봉이 수직으로 체결된 용접 장치 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE273695T1 (de) | 2000-06-28 | 2004-09-15 | Smithkline Beecham Plc | Nassvermahlung |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| US20070219223A1 (en) | 2006-03-07 | 2007-09-20 | Endacea, Inc. | Compositions and methods for treating respiratory disorders |
| US8058227B2 (en) | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| EP2684564A1 (en) | 2008-04-17 | 2014-01-15 | Sanofi | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation |
| JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体 |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| PE20121336A1 (es) | 2009-12-01 | 2012-11-03 | Abbvie Inc | Nuevos compuestos triciclicos |
| PT3354652T (pt) | 2010-03-10 | 2020-07-20 | Incyte Holdings Corp | Derivados de piperidin-4-ilazetidina como inibidores de jak1 |
| RU2013120966A (ru) | 2010-10-08 | 2014-11-20 | Эббви Инк. | ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| AU2013274030B2 (en) | 2012-06-15 | 2016-07-07 | Sun Pharmaceutical Industries, Inc. | Deuterated derivatives of ruxolitinib |
| CA2880083A1 (en) | 2012-08-17 | 2014-02-20 | Concert Pharmaceuticals, Inc. | Deuterated baricitinib |
| CN104918945B (zh) | 2012-11-01 | 2018-01-05 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
| WO2014138168A1 (en) | 2013-03-06 | 2014-09-12 | Incyte Corporation | Processes and intermediates for making a jak inhibitor |
| SMT201900223T1 (it) | 2013-05-17 | 2019-07-11 | Incyte Corp | Sale di bipirazolo come inibitore di jak |
| SG10201801069QA (en) * | 2013-08-07 | 2018-03-28 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| EP3060234A1 (en) * | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
| JP6576941B2 (ja) * | 2014-02-28 | 2019-09-18 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | 骨髄異形成症候群の治療のためのｊａｋ１阻害剤 |
| CN106687462A (zh) | 2014-04-30 | 2017-05-17 | 因赛特公司 | Jak1抑制剂的制备方法以及其新形式 |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| HK1252685A1 (zh) | 2015-11-03 | 2019-05-31 | Theravance Biopharma R&D Ip, Llc | 用於治疗呼吸疾病的jak激酶抑制剂化合物 |
| CN105294699B (zh) * | 2015-12-04 | 2019-06-11 | 上海勋和医药科技有限公司 | 巴瑞替尼的制备方法 |
| KR102399848B1 (ko) * | 2016-10-03 | 2022-05-19 | 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 | 신규한 jak1 선택적 억제제 및 그 용도 |
| EP3327020A1 (en) * | 2016-11-29 | 2018-05-30 | Sandoz Ag | Citrate salts of a janus kinase (jak) inhibitor |
| BR112019018648A2 (pt) | 2017-03-09 | 2020-06-16 | Theravance Biopharma R&D Ip, Llc | Inibidores de jak contendo uma amida heterocíclica com 4 membros |
| US10406148B2 (en) | 2017-05-01 | 2019-09-10 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| EA202091830A1 (ru) | 2018-01-30 | 2020-12-29 | Инсайт Корпорейшн | Способы и промежуточные соединения для получения ингибитора jak |
| IL311485B1 (en) | 2018-02-16 | 2026-01-01 | Incyte Corp | JAK1 pathway inhibitors for the treatment of cytokine-related disorders |
| MD3773593T2 (ro) | 2018-03-30 | 2024-10-31 | Incyte Corp | Tratament hidradenitei supurative utilizând inhibitori ai JAK |
| CA3097025A1 (en) | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| CA3123596A1 (en) | 2018-12-19 | 2020-06-25 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
| MA55201A (fr) | 2019-03-05 | 2022-01-12 | Incyte Corp | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
-
2020
- 2020-03-05 MA MA055201A patent/MA55201A/fr unknown
- 2020-03-05 UA UAA202105585A patent/UA130579C2/uk unknown
- 2020-03-05 AU AU2020232757A patent/AU2020232757B2/en active Active
- 2020-03-05 EA EA202192426A patent/EA202192426A1/ru unknown
- 2020-03-05 WO PCT/US2020/021088 patent/WO2020181034A1/en not_active Ceased
- 2020-03-05 JP JP2021552624A patent/JP2022524997A/ja active Pending
- 2020-03-05 SG SG11202109563WA patent/SG11202109563WA/en unknown
- 2020-03-05 EP EP20713496.6A patent/EP3934651A1/en active Pending
- 2020-03-05 CN CN202080024215.0A patent/CN114007621A/zh active Pending
- 2020-03-05 CA CA3132371A patent/CA3132371A1/en active Pending
- 2020-03-05 MX MX2021010545A patent/MX2021010545A/es unknown
- 2020-03-05 US US16/810,045 patent/US11406640B2/en active Active
- 2020-03-05 KR KR1020217031644A patent/KR20210137087A/ko active Pending
- 2020-03-05 PH PH1/2021/552130A patent/PH12021552130A1/en unknown
- 2020-03-05 IL IL285999A patent/IL285999B2/en unknown
- 2020-03-05 EP EP25213638.7A patent/EP4691567A3/en active Pending
-
2021
- 2021-09-02 MX MX2024007081A patent/MX2024007081A/es unknown
-
2022
- 2022-06-30 US US17/854,443 patent/US11896595B2/en active Active
-
2025
- 2025-02-21 JP JP2025026650A patent/JP2025087734A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020232757A1 (en) | 2021-10-07 |
| EP4691567A3 (en) | 2026-04-29 |
| WO2020181034A1 (en) | 2020-09-10 |
| JP2022524997A (ja) | 2022-05-11 |
| CN114007621A (zh) | 2022-02-01 |
| MX2024007081A (es) | 2024-06-21 |
| MA55201A (fr) | 2022-01-12 |
| SG11202109563WA (en) | 2021-09-29 |
| EP3934651A1 (en) | 2022-01-12 |
| IL285999B1 (en) | 2025-09-01 |
| PH12021552130A1 (en) | 2022-08-31 |
| KR20210137087A (ko) | 2021-11-17 |
| EP4691567A2 (en) | 2026-02-11 |
| UA130579C2 (uk) | 2026-03-25 |
| IL285999B2 (en) | 2026-01-01 |
| US20220331325A1 (en) | 2022-10-20 |
| MX2021010545A (es) | 2021-11-17 |
| IL285999A (en) | 2021-10-31 |
| US11406640B2 (en) | 2022-08-09 |
| JP2025087734A (ja) | 2025-06-10 |
| US20200281931A1 (en) | 2020-09-10 |
| EA202192426A1 (ru) | 2021-11-15 |
| US11896595B2 (en) | 2024-02-13 |
| AU2020232757B2 (en) | 2025-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020232757B2 (en) | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction | |
| CA3158254C (en) | Treatment of b-cell malignancies by a combination jak and pi3k inhibitors | |
| CA2940659C (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
| HUE029226T2 (en) | Novel heterocyclic derivatives and their use in the treatment of neurological disorders | |
| US10220032B2 (en) | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors | |
| TW202039459A (zh) | Alk5 抑制劑 | |
| US20240293411A1 (en) | Combination therapy comprising jak pathway inhibitor and rock inhibitor | |
| CN109535164A (zh) | Jak激酶抑制剂及其制备方法和在医药领域的应用 | |
| EA044660B1 (ru) | Ингибиторы путей jak1 для лечения хронической дисфункции аллотрансплантата легких | |
| EA050167B1 (ru) | Комбинированная терапия, включающая ингибитор пути jak и ингибитор rock | |
| CN117120055A (zh) | 包含jak通路抑制剂和rock抑制剂的组合疗法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240304 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250303 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250304 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250304 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250318 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250716 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250717 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250725 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250725 |